0000000000121686
AUTHOR
A. Grandvuillemin
Étude des cancers secondaires dans les lymphomes non hodgkiniens au sein d’un registre : impact du rituximab
Introduction Le nombre de survivants d’un lymphome folliculaire (LF) ou d’un lymphome B diffus a grandes cellules (LBDGC) est en augmentation. L’etude des cancers secondaires est un enjeu important de sante publique. Le risque lie a la chimiotherapie conventionnelle est bien decrit, mais peu de donnees existent pour le rituximab. Methode Etude retrospective au sein du Registre des hemopathies malignes de Cote d’or (RHEMCO) comparant l’incidence des cancers secondaires avant/apres l’introduction du rituximab, chez les patients ayant un LF ou un LBDGC diagnostique entre 1990 et 2010. La comparaison du taux de cancers secondaires observe au taux attendu dans la population francaise a ete expri…
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial
SummaryBackground A phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads was performed in cirrhotic patients with hepatocellular carcinoma (HCC). Aim To estimate the maximum-tolerated dose (MTD) and to assess safety, efficacy, pharmacokinetics and quality of life. Methods Patients received a single TACE session with injection of 2 mL drug-eluting beads (DEBs; DC Bead 300–500 μm) loaded with idarubicin. The idarubicin dose was escalated according to a modified continuous reassessment method. MTD was defined as the dose level closest to that causing dose-limiting toxicity (DLT) in 20% of patients. Results Twenty-one patients were enrolled, inclu…